Journal article
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Abstract
BACKGROUND: Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement. Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin. We assessed efficacy and safety of these drugs after elective total knee replacement.
METHODS: In ADVANCE-2, a multicentre, randomised, double-blind phase 3 study, …
Authors
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P; investigators TA
Journal
The Lancet, Vol. 375, No. 9717, pp. 807–815
Publisher
Elsevier
Publication Date
3 2010
DOI
10.1016/s0140-6736(09)62125-5
ISSN
0140-6736